Patents Examined by Taofiq A. Solola
  • Patent number: 11319317
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 3, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Patent number: 11319324
    Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 3, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
  • Patent number: 11319320
    Abstract: This application relates to compounds of formulae (I) and (II) and compositions thereof useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 3, 2022
    Assignee: SNAP BIO, INC.
    Inventors: Mark J. Burk, Brandon Chen, Jingyi Li, Shawn Bachan
  • Patent number: 11318141
    Abstract: Disclosed are methods and compositions related to STK1 inhibitors, such as Inh2-B1 (methyl 5-oxo-3-(phenyl carbamoyl)-1-thioxo-4,5dihydro[1,3]thiazolo[3,4-a]quinazoline-8-carboxylate). The STK1 inhibitors can act as an antibiotic resistance breakers against multidrug-resistant Staphylococcus aureus.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Ohio State innovation Foundation
    Inventor: Vijay Pancholi
  • Patent number: 11311517
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 26, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • Patent number: 11311036
    Abstract: Glycine is an organic compound that can be used in the making of a synthetic base that obviates all the drawbacks of strong bases such as sodium hydroxide. The new compound is made by dissolving glycine in water and adding calcium hydroxide at a molar ration of about 1:1. Next, sodium percarbonate is dissolved in the solution to produce the new compound, which can be referred to as glycine hydroxide.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Green Products & Technologies, L.L.C.
    Inventor: John T. MacDonald
  • Patent number: 11312696
    Abstract: The invention relates to a method for directly producing morin derivatives and high-purity morin of formula (I). The invention also relates to morin derivatives and high-purity morin that can be obtained using the claimed method.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 26, 2022
    Assignee: ORSATEC GMBH
    Inventors: Thomas Lindel, Steffen Mende
  • Patent number: 11312725
    Abstract: Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 26, 2022
    Assignee: Sytheon Limited
    Inventor: Ratan K Chaudhuri
  • Patent number: 11311550
    Abstract: A composition for the treatment of cellulitis is provided that includes an antibiotic. The composition may also include an analgesic, an anaesthetic, or a combination thereof. A method use is also provided by which the composition is applied topically or to affected skin. A method of use is also provided prior to a medical procedure involving an incision through the skin of a patient in a predetermined area, the method including the application, to the predetermined area and prior to the procedure of the composition.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: April 26, 2022
    Assignees: Multimode Medical Holdings Inc.
    Inventors: Patrick Musitano, Paul Zalzal
  • Patent number: 11298347
    Abstract: Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: April 12, 2022
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Hakon Hakonarson, Charlly Kao
  • Patent number: 11292795
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: April 5, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 11286245
    Abstract: Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: March 29, 2022
    Assignee: MIDDLE TENNESSEE STATE UNIVERSITY
    Inventors: Jeannie Stubblefield, Zachary E. Taylor, Scott Handy, Anthony Newsome
  • Patent number: 11278622
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 22, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandron Donadelli, Dario Resemini
  • Patent number: 11278521
    Abstract: Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 22, 2022
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL—PSG IV (024)
    Inventors: Niketa A. Patel, Jianfeng Cai
  • Patent number: 11279707
    Abstract: Compounds of the present application or pharmaceutically acceptable salts thereof are provided and methods involving compounds of the present application as effective inhibitors of NEK are also provided.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 22, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Quan Cai, Tinghu Zhang
  • Patent number: 11274109
    Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 15, 2022
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Oliver Schadt, Christina Esdar
  • Patent number: 11273150
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: March 15, 2022
    Assignee: LENZ THERAPEUTICS, INC.
    Inventor: Gerald Horn
  • Patent number: 11274080
    Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: March 15, 2022
    Assignee: Novartis AG
    Inventor: Gebhard Thoma
  • Patent number: 11261173
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 1, 2022
    Assignee: PHARVARIS NETHERLANDS B.V.
    Inventors: Christoph Gibson, Joern Saupe, Horst-Dieter Ambrosi, Lars Ole Haustedt
  • Patent number: 11262353
    Abstract: Materials and methods for the design of hybrid materials comprising a conducting matrix, organic modifiers/linkers and modifying molecules.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 1, 2022
    Assignee: UNM Rainforest Innovations
    Inventors: Nikolai Kalugin, Alexey Serov, Lindsay Candelaria, Peter Kalugin